Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Metabotropic glutamate receptor 1 and glutamate signaling in human melanoma.

Namkoong J, Shin SS, Lee HJ, Marín YE, Wall BA, Goydos JS, Chen S.

Cancer Res. 2007 Mar 1;67(5):2298-305.

2.

The glutamate release inhibitor Riluzole decreases migration, invasion, and proliferation of melanoma cells.

Le MN, Chan JL, Rosenberg SA, Nabatian AS, Merrigan KT, Cohen-Solal KA, Goydos JS.

J Invest Dermatol. 2010 Sep;130(9):2240-9. doi: 10.1038/jid.2010.126. Epub 2010 May 27.

3.

Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.

Lee HJ, Wall BA, Wangari-Talbot J, Shin SS, Rosenberg S, Chan JL, Namkoong J, Goydos JS, Chen S.

Clin Cancer Res. 2011 Nov 15;17(22):7080-92. doi: 10.1158/1078-0432.CCR-11-0098. Epub 2011 Aug 15. Erratum in: Clin Cancer Res. 2012 Mar 1;18(5):1484.

4.

Functional effects of GRM1 suppression in human melanoma cells.

Wangari-Talbot J, Wall BA, Goydos JS, Chen S.

Mol Cancer Res. 2012 Nov;10(11):1440-50. doi: 10.1158/1541-7786.MCR-12-0158. Epub 2012 Jul 13.

5.

Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer.

Speyer CL, Smith JS, Banda M, DeVries JA, Mekani T, Gorski DH.

Breast Cancer Res Treat. 2012 Apr;132(2):565-73. doi: 10.1007/s10549-011-1624-x. Epub 2011 Jun 17.

6.

Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia.

Pollock PM, Cohen-Solal K, Sood R, Namkoong J, Martino JJ, Koganti A, Zhu H, Robbins C, Makalowska I, Shin SS, Marin Y, Roberts KG, Yudt LM, Chen A, Cheng J, Incao A, Pinkett HW, Graham CL, Dunn K, Crespo-Carbone SM, Mackason KR, Ryan KB, Sinsimer D, Goydos J, Reuhl KR, Eckhaus M, Meltzer PS, Pavan WJ, Trent JM, Chen S.

Nat Genet. 2003 May;34(1):108-12.

PMID:
12704387
7.

Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells.

Wall BA, Wangari-Talbot J, Shin SS, Schiff D, Sierra J, Yu LJ, Khan A, Haffty B, Goydos JS, Chen S.

Pigment Cell Melanoma Res. 2014 Mar;27(2):263-74. doi: 10.1111/pcmr.12207. Epub 2014 Jan 22.

8.

Activation of the glutamate receptor GRM1 enhances angiogenic signaling to drive melanoma progression.

Wen Y, Li J, Koo J, Shin SS, Lin Y, Jeong BS, Mehnert JM, Chen S, Cohen-Sola KA, Goydos JS.

Cancer Res. 2014 May 1;74(9):2499-509. doi: 10.1158/0008-5472.CAN-13-1531. Epub 2014 Feb 3.

9.

Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells.

Teh JL, Shah R, La Cava S, Dolfi SC, Mehta MS, Kongara S, Price S, Ganesan S, Reuhl KR, Hirshfield KM, Karantza V, Chen S.

Breast Cancer Res Treat. 2015 May;151(1):57-73. doi: 10.1007/s10549-015-3365-8. Epub 2015 Apr 10.

PMID:
25859923
10.

Oncogenic activities of metabotropic glutamate receptor 1 (Grm1) in melanocyte transformation.

Shin SS, Namkoong J, Wall BA, Gleason R, Lee HJ, Chen S.

Pigment Cell Melanoma Res. 2008 Jun;21(3):368-78. doi: 10.1111/j.1755-148X.2008.00452.x. Epub 2008 Apr 23.

11.

Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells.

Martino JJ, Wall BA, Mastrantoni E, Wilimczyk BJ, La Cava SN, Degenhardt K, White E, Chen S.

Oncogene. 2013 Sep 12;32(37):4366-76. doi: 10.1038/onc.2012.471. Epub 2012 Oct 22.

12.

From existing therapies to novel targets: a current view on melanoma.

Namkoong J, Martino JJ, Chen S.

Front Biosci. 2006 Sep 1;11:2081-92. Review.

PMID:
16720295
13.

Stimulation of oncogenic metabotropic glutamate receptor 1 in melanoma cells activates ERK1/2 via PKCepsilon.

Marín YE, Namkoong J, Cohen-Solal K, Shin SS, Martino JJ, Oka M, Chen S.

Cell Signal. 2006 Aug;18(8):1279-86. Epub 2005 Nov 21.

PMID:
16305822
14.

Blocking glutamate-mediated signalling inhibits human melanoma growth and migration.

Song Z, He CD, Liu J, Sun C, Lu P, Li L, Gao L, Zhang Y, Xu Y, Shan L, Liu Y, Zou W, Zhang Y, Gao H, Gao W.

Exp Dermatol. 2012 Dec;21(12):926-31. doi: 10.1111/exd.12048.

PMID:
23171453
15.

Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo.

Khan AJ, Wall B, Ahlawat S, Green C, Schiff D, Mehnert JM, Goydos JS, Chen S, Haffty BG.

Clin Cancer Res. 2011 Apr 1;17(7):1807-14. doi: 10.1158/1078-0432.CCR-10-1276. Epub 2011 Feb 15.

16.

Glutamatergic signaling in cellular transformation.

Teh JL, Chen S.

Pigment Cell Melanoma Res. 2012 May;25(3):331-42. doi: 10.1111/j.1755-148X.2012.00983.x. Epub 2012 Feb 20. Review.

PMID:
22273393
17.

AKT2 is a downstream target of metabotropic glutamate receptor 1 (Grm1).

Shin SS, Wall BA, Goydos JS, Chen S.

Pigment Cell Melanoma Res. 2010 Feb;23(1):103-11. doi: 10.1111/j.1755-148X.2009.00648.x. Epub 2009 Oct 20.

18.

Grm5 expression is not required for the oncogenic role of Grm1 in melanocytes.

Marín YE, Namkoong J, Shin SS, Raines J, Degenhardt K, White E, Chen S.

Neuropharmacology. 2005;49 Suppl 1:70-9.

PMID:
16040064
19.

A phase 0 trial of riluzole in patients with resectable stage III and IV melanoma.

Yip D, Le MN, Chan JL, Lee JH, Mehnert JA, Yudd A, Kempf J, Shih WJ, Chen S, Goydos JS.

Clin Cancer Res. 2009 Jun 1;15(11):3896-902. doi: 10.1158/1078-0432.CCR-08-3303. Epub 2009 May 19.

20.

Riluzole is a radio-sensitizing agent in an in vivo model of brain metastasis derived from GRM1 expressing human melanoma cells.

Wall BA, Yu LJ, Khan A, Haffty B, Goydos JS, Chen S.

Pigment Cell Melanoma Res. 2015 Jan;28(1):105-9. doi: 10.1111/pcmr.12327. Epub 2014 Nov 28.

PMID:
25363352
Items per page

Supplemental Content

Write to the Help Desk